The global immune checkpoint agents market is expected to grow at a CAGR of 12.2% during the forecast period, from 2021 to 2030. The growth of this market is driven by the increasing incidence of cancer and rising demand for immunotherapy drugs.
AntP1 Drug segment accounted for the largest share in the global immune checkpoint agents market in 2018, followed by AntPL1 Drug and CTLA4 segments. AntP1 Drug segment is expected to maintain its dominance throughout the forecast period due to its high efficacy against various types of cancers such as lung cancer, colorectal cancer, breast cancer      and prostate cancer.
North America accounted for the largest share in global immune checkpoint agents market in 2018 due to high prevalence rates of cancers such as lung cancer, colorectal cancer, breast cancer and prostate cancers among other factors such as higher awareness about immunotherapy drugs among patients with these types of cancers. North America is also expected to maintain its dominance throughout the forecast period owing to increasing number of patients diagnosed with these types of cancers every year coupled with growing awareness about immunotherapy drugs among patients diagnosed with these types of cancers which will drive demand for these drugs over time.
-The global market for immune checkpoint agents is expected to grow at a CAGR of 12.2% from 2018 to 2023.
-Immune checkpoint inhibitors are a type of immunotherapy that blocks the interaction between immune cells and cancer cells or other pathogens This prevents the immune system from attacking healthy tissue and allows it to attack cancerous cells or pathogens instead.
Industry Growth Insights published a new data on “Immune Checkpoint Agents Market”. The research report is titled “Immune Checkpoint Agents Market research by Types (Anti-PD-L1 Drug, Anti-PD-1 Drug, CTLA4), By Applications (Lung Cancer, Colorectal Cancer, Breast Cancer , Prostate Cancer, Melanoma, Blood Cancers), By Players/Companies Bristol Myers Squibb, Merck, AstraZeneca, Roche”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Immune Checkpoint Agents Market Research Report
By Type
Anti-PD-L1 Drug, Anti-PD-1 Drug, CTLA4
By Application
Lung Cancer, Colorectal Cancer, Breast Cancer , Prostate Cancer, Melanoma, Blood Cancers
By Companies
Bristol Myers Squibb, Merck, AstraZeneca, Roche
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
243
Number of Tables & Figures
171
Customization Available
Yes, the report can be customized as per your need.
Global Immune Checkpoint Agents Market Report Segments:
The global Immune Checkpoint Agents market is segmented on the basis of:
Types
Anti-PD-L1 Drug, Anti-PD-1 Drug, CTLA4
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Lung Cancer, Colorectal Cancer, Breast Cancer , Prostate Cancer, Melanoma, Blood Cancers
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Bristol Myers Squibb
- Merck
- AstraZeneca
- Roche
Highlights of The Immune Checkpoint Agents Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Anti-PD-L1 Drug
- Anti-PD-1 Drug
- CTLA4
- By Application:
- Lung Cancer
- Colorectal Cancer
- Breast CancerÂ
- Prostate Cancer
- Melanoma
- Blood Cancers
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Immune Checkpoint Agents Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Immune checkpoint agents are a type of cancer therapy that help the body's immune system fight cancer. These drugs work by stopping the growth of tumors by blocking certain proteins that help tumors grow.
Some of the major players in the immune checkpoint agents market are Bristol Myers Squibb, Merck, AstraZeneca, Roche.
The immune checkpoint agents market is expected to register a CAGR of 12.2%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Immune Checkpoint Agents Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Immune Checkpoint Agents Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Immune Checkpoint Agents Market - Supply Chain
4.5. Global Immune Checkpoint Agents Market Forecast
4.5.1. Immune Checkpoint Agents Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Immune Checkpoint Agents Market Size (000 Units) and Y-o-Y Growth
4.5.3. Immune Checkpoint Agents Market Absolute $ Opportunity
5. Global Immune Checkpoint Agents Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Immune Checkpoint Agents Market Size and Volume Forecast by Type
5.3.1. Anti-PD-L1 Drug
5.3.2. Anti-PD-1 Drug
5.3.3. CTLA4
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Immune Checkpoint Agents Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Immune Checkpoint Agents Market Size and Volume Forecast by Application
6.3.1. Lung Cancer
6.3.2. Colorectal Cancer
6.3.3. Breast Cancer
6.3.4. Prostate Cancer
6.3.5. Melanoma
6.3.6. Blood Cancers
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Immune Checkpoint Agents Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Immune Checkpoint Agents Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Immune Checkpoint Agents Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Immune Checkpoint Agents Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Immune Checkpoint Agents Demand Share Forecast, 2019-2026
9. North America Immune Checkpoint Agents Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Immune Checkpoint Agents Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Immune Checkpoint Agents Market Size and Volume Forecast by Application
9.4.1. Lung Cancer
9.4.2. Colorectal Cancer
9.4.3. Breast Cancer
9.4.4. Prostate Cancer
9.4.5. Melanoma
9.4.6. Blood Cancers
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Immune Checkpoint Agents Market Size and Volume Forecast by Type
9.7.1. Anti-PD-L1 Drug
9.7.2. Anti-PD-1 Drug
9.7.3. CTLA4
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Immune Checkpoint Agents Demand Share Forecast, 2019-2026
10. Latin America Immune Checkpoint Agents Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Immune Checkpoint Agents Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Immune Checkpoint Agents Market Size and Volume Forecast by Application
10.4.1. Lung Cancer
10.4.2. Colorectal Cancer
10.4.3. Breast Cancer
10.4.4. Prostate Cancer
10.4.5. Melanoma
10.4.6. Blood Cancers
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Immune Checkpoint Agents Market Size and Volume Forecast by Type
10.7.1. Anti-PD-L1 Drug
10.7.2. Anti-PD-1 Drug
10.7.3. CTLA4
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Immune Checkpoint Agents Demand Share Forecast, 2019-2026
11. Europe Immune Checkpoint Agents Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Immune Checkpoint Agents Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Immune Checkpoint Agents Market Size and Volume Forecast by Application
11.4.1. Lung Cancer
11.4.2. Colorectal Cancer
11.4.3. Breast Cancer
11.4.4. Prostate Cancer
11.4.5. Melanoma
11.4.6. Blood Cancers
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Immune Checkpoint Agents Market Size and Volume Forecast by Type
11.7.1. Anti-PD-L1 Drug
11.7.2. Anti-PD-1 Drug
11.7.3. CTLA4
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Immune Checkpoint Agents Demand Share, 2019-2026
12. Asia Pacific Immune Checkpoint Agents Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Immune Checkpoint Agents Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Immune Checkpoint Agents Market Size and Volume Forecast by Application
12.4.1. Lung Cancer
12.4.2. Colorectal Cancer
12.4.3. Breast Cancer
12.4.4. Prostate Cancer
12.4.5. Melanoma
12.4.6. Blood Cancers
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Immune Checkpoint Agents Market Size and Volume Forecast by Type
12.7.1. Anti-PD-L1 Drug
12.7.2. Anti-PD-1 Drug
12.7.3. CTLA4
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Immune Checkpoint Agents Demand Share, 2019-2026
13. Middle East & Africa Immune Checkpoint Agents Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Immune Checkpoint Agents Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Immune Checkpoint Agents Market Size and Volume Forecast by Application
13.4.1. Lung Cancer
13.4.2. Colorectal Cancer
13.4.3. Breast Cancer
13.4.4. Prostate Cancer
13.4.5. Melanoma
13.4.6. Blood Cancers
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Immune Checkpoint Agents Market Size and Volume Forecast by Type
13.7.1. Anti-PD-L1 Drug
13.7.2. Anti-PD-1 Drug
13.7.3. CTLA4
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Immune Checkpoint Agents Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Immune Checkpoint Agents Market: Market Share Analysis
14.2. Immune Checkpoint Agents Distributors and Customers
14.3. Immune Checkpoint Agents Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. Bristol Myers Squibb
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Merck
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. AstraZeneca
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Roche
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. COMPANY5
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. COMPANY6
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. COMPANY7
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. COMPANY8
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. COMPANY9
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook
